Synbio International, Inc. (OTC: SYIN) announced today that it has entered into a Strategic Licensing, Manufacturing, Supply and Revenue Sharing Agreement with MD PHD Wellness, Inc., granting Synbio exclusive rights to commercialize MD PHD Wellness' proprietary nutraceutical formulations throughout the United States and Canada. The agreement covers a flagship anti-anxiety nutraceutical formulation, which will be marketed under Synbio's Healing Force™ brand, and establishes a framework for future product evaluations and commercialization.
This partnership provides Synbio with immediate access to proprietary products without the time and cost burden of in-house development, significantly accelerating the company's path to revenue generation. Under the terms, MD PHD Wellness will handle product development, manufacturing, quality assurance, and supply chain, while Synbio focuses on branding, marketing, sales, and distribution. Profits from product sales will be shared after recovering approved manufacturing and commercialization costs.
Claudio Solitario, CEO of Synbio International, stated, "This agreement represents a transformational milestone for Synbio. Rather than building a nutraceutical business product by product, we have established a strategic partnership that combines MD PHD's product development and manufacturing expertise with Synbio's commercialization capabilities. It gives Synbio immediate access to proprietary products capable of generating near-term commercial revenue while establishing a framework to expand our wellness portfolio over time." He added, "We believe this partnership creates an efficient and scalable business model. As the global nutraceutical market continues its rapid expansion, Synbio is now positioned to participate through a growing portfolio of scientifically developed products."
MD PHD Wellness was founded by Dr. Robert Lawrence, a physician and scientist with two Ph.D. degrees in Nuclear Physics and Biomedical Engineering, whose career spans medicine, biomedical engineering, microbiology, pharmacology, and nutraceutical development. Co-founder Dr. David Anderson, an experienced physician and researcher, played a key role in developing the licensed formulations and has extensive expertise in nutraceuticals and medical technologies. His background includes serving as a Research Physician and Senior Research Scientist at a prominent New York-based university, with work recognized in Marquis Who's Who.
The agreement advances Synbio's broader strategy of building a diversified healthcare company that pairs near-term revenue from commercial wellness products with longer-term value from its AI-driven mental health technologies. This dual-track approach is intended to provide multiple avenues for growth and establish recurring revenue to support continued innovation.
Synbio International is focused on clinically validating an AI-driven software that screens for mental health conditions using facial analysis. Through strategic partnerships and research collaborations, the company aims to develop and validate science-based solutions to improve quality of life and empower healthcare providers. To generate early revenue while the software advances, Synbio plans to launch a line of nutraceutical products sold directly to consumers online in 2026.
For more information about the company, visit www.synbiointl.com.
